SecBot SecBot
PRESS-RELEASE ·Filed Apr 11, 2026

BNTX

BioNTech SE
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Trastuzumab pamirtecan represents a potentially practice-changing therapy in recurrent endometrial cancer, a space with few effective options. With Breakthrough Therapy designation and strong Phase 2 data across HER2 expression levels, the path toward BLA filing in 2026 enhances near-term catalyst potential. Traders should monitor upcoming regulatory interactions and Phase 3 readouts, particularly DYNASTY-Breast02 later this year.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$96.70
T+0 close · Apr 11, 2026 · via day close
Latest settled
−3.28%
T+60 · $93.53
Vs SPY
−12.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $96.70entry
  2. T+1 · 7mo ago +1.77%α +0.56% · $98.41
  3. T+5 · 7mo ago +8.78%α +5.48% · $105.19
  4. T+20 · 6mo ago −3.47%α −11.20% · $93.34
  5. T+60 · 4mo ago −3.28%α −12.20% · $93.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in advanced endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival across all HER2 expression levels, with a manageable safety profile. The data support the drug's potential in a high-unmet-need population, including those with prior checkpoint inhibitor exposure.

Key Facts

  • Phase 2 cohort of 145 patients with advanced HER2-expressing endometrial cancer met primary endpoint of objective response rate (ORR).
  • Confirmed ORR was 47.9% in centrally tested patients (n=96), with 49.3% in those previously treated with checkpoint inhibitors.
  • Median progression-free survival was 8.1 months (95% CI: 5.5, 11.8) in centrally tested patients.
  • Trastuzumab pamirtecan showed activity across all HER2 expression levels (IHC1+, IHC2+, IHC3+) and in real-world populations including those with visceral metastases.
  • Safety profile was manageable; grade ≥3 treatment-related adverse events occurred in 46.9% of patients, with 4.8% experiencing grade ≥3 ILD/pneumonitis.
  • FDA has granted Fast Track and Breakthrough Therapy designations for this indication; BLA submission planned in 2026 pending regulatory feedback.
  • Global Phase 3 trial (Fern-EC-01) is ongoing, with plans to file BLA subject to FDA input.

Financial Impact

High-value oncology pipeline advancement with registrational potential; could expand BNTX's market beyond mRNA into targeted cancer therapies.

pipeline valuemarket opportunityregulatory milestones

Risk Factors

  • Phase 2 data may not be replicated in larger Phase 3 trials.
  • Safety signals, including 4.8% grade ≥3 ILD/pneumonitis, could impact regulatory or commercial acceptance.
  • Dependence on successful collaboration with DualityBio for development and commercialization.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272109

Track record

38 reports on BNTX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 11, 2026